BENDAMUSTINE HYDROCHLORIDE FOR INJECTION 100 MG — DIN 02542005
BENDAMUSTINE HYDROCHLORIDE : 100 MG · EUGIA PHARMA INC. · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is BENDAMUSTINE HYDROCHLORIDE FOR INJECTION?
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION 100 MG contains BENDAMUSTINE HYDROCHLORIDE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02542005, held by EUGIA PHARMA INC., supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 08-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BENDAMUSTINE HYDROCHLORIDE FOR INJECTION used for?
Relapsed indolent B-cell non-Hodgkin lymphoma (NHL) post-rituximab; untreated symptomatic chronic lymphocytic leukemia (CLL).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Bendamustine cost around the world?
Bendamustine is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Lebanon publishes a public price (USD, Decision 119/1). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 4 | 8 | AUD███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
19 pack listings across 14 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every Bendamustine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Bendamustine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Bendamustine, across 18 DINs, of which 11 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACCORD HEALTHCARE INC | 2 | 2 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 2 | 2 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | Sourceable in Canada |
| NATCO PHARMA (CANADA) INC | 2 | 2 | NAT-BENDAMUSTINE | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | TREANDA | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | BENVYON | Sourceable in Canada |
| HIKMA CANADA LIMITED | 2 | 0 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | No marketed DIN |
| JAMP PHARMA CORPORATION | 2 | 0 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | No marketed DIN |
| DR REDDY'S LABORATORIES LTD | 1 | 0 | ESAMUZE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 25 mg in 26 mL amber single-use vials; 100 mg in 60 mL amber single-use vials. |
| Storage | Store at room temperature (15-30°C). Retain in original package to protect from light. Admixture stable 24h refrigerated or 3h at room temperature. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Bendamustine |
|---|---|
| ATC code | L01AA09 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02542005 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2542005 |
| Brand name | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION |
| Generic / active ingredient | BENDAMUSTINE HYDROCHLORIDE : 100 MG |
| Market authorization holder | EUGIA PHARMA INC. |
| Health Canada schedule | Prescription |
| ATC code | L01AA09 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01AA |
| Current status | MARKETED |
| Status date | 08-Oct-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
NHL: 120 mg/m2 IV over 60 min (Days 1, 2 of 21-day cycle). CLL: 100 mg/m2 IV over 30 min (Days 1, 2 of 28-day cycle). Dose reductions for Grade 3/4 toxicities.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to bendamustine, mannitol, or any ingredient in the formulation or component of the container. Serious infections.
Warnings and precautions
Serious risks: cardiac failure, myelosuppression, fatal infections, secondary malignancies, and severe skin reactions (SJS, TEN, DRESS). Monitor for tumor lysis syndrome and PML.
Is Bendamustine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for BENDAMUSTINE HYDROCHLORIDE FOR INJECTION
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
11 of 18 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 25 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | 02541998 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 25 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02509253 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 25 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02496852 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02496860 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02509261 |
| BENVYON | 25 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02524309 |
| NAT-BENDAMUSTINE | 100 MG | POWDER FOR SOLUTION | NATCO PHARMA (CANADA) INC | MARKETED | 02496895 |
| NAT-BENDAMUSTINE | 25 MG | POWDER FOR SOLUTION | NATCO PHARMA (CANADA) INC | MARKETED | 02496887 |
| TREANDA | 25 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02392550 |
| TREANDA | 100 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02392569 |
2 · Same class — other molecules in ATC L01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE FOR INJECTION · CYCLOPHOSPHAMIDE FOR INJECTION USP · CYTOXAN PWS FOR INJ 1000MG/VIAL · CYTOXAN PWS FOR INJ 2000MG/VIAL · +10 more | 28 | 12 | Yes |
| Bendamustine | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION · BENVYON · ESAMUZE · NAT-BENDAMUSTINE · +1 more | 18 | 11 | Yes |
| Melphalan | ALKERAN · MELPHALAN FOR INJECTION · TARO-MELPHALAN | 8 | 4 | Yes |
| Ifosfamide | IFEX · IFEX PWS 1GM/VIAL · IFEX PWS 2G/VIAL · IFEX PWS 3GM/VIAL · +1 more | 7 | 2 | Yes |
| Chlormethine | LEDAGA · MUSTARGEN | 2 | 1 | Yes |
| Chlorambucil | LEUKERAN | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01AX | Dacarbazine · Temozolomide | 42 | 26 |
| L01AC | Thiotepa | 9 | 6 |
| L01AB | Busulfan · Treosulfan | 10 | 4 |
| L01AD | Carmustine · Lomustine · Streptozocin | 8 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BENDAMUSTINE HYDROCHLORIDE FOR INJECTION called?
The same molecule, Bendamustine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| BENDAMUSTINE EUGIA | Latin | Australia |
| BENDAMUSTINE HYDROCHLORIDE | Latin | Lebanon |
| BENDAMUSTINE HYDROCHLORIDE MEDSURGE | Latin | Australia |
| Bendamustine Sandoz | Latin | Australia |
| Bendamustine Viatris | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for BENDAMUSTINE HYDROCHLORIDE FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.